A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
At a Dermatology Times Case-Based Roundtable event, Carolyn Goh, MD, led clinicians through a discussion of severity scoring, patient-reported outcomes, CYP2C9 testing, and long-term monitoring across 3 alopecia areata cases.